MX344435B - Compuestos antitromboticos. - Google Patents

Compuestos antitromboticos.

Info

Publication number
MX344435B
MX344435B MX2013014946A MX2013014946A MX344435B MX 344435 B MX344435 B MX 344435B MX 2013014946 A MX2013014946 A MX 2013014946A MX 2013014946 A MX2013014946 A MX 2013014946A MX 344435 B MX344435 B MX 344435B
Authority
MX
Mexico
Prior art keywords
thrombotic compounds
compounds
thrombotic
oxoclopidogrel
thrombo
Prior art date
Application number
MX2013014946A
Other languages
English (en)
Other versions
MX2013014946A (es
Inventor
Kumar Ashok
Rajanikant Soudagar Satish
Byju Nellithanath Thankachen
Sahal Gaurav
Prashant Mathur Arpana
Pandurang Gawade Sanjay
Kanji Bhadra Dinesh
Moje Devki
Original Assignee
Ipca Laboratories Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd * filed Critical Ipca Laboratories Ltd *
Publication of MX2013014946A publication Critical patent/MX2013014946A/es
Publication of MX344435B publication Critical patent/MX344435B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Nuevos compuestos, a saber (7aS,2'S)-2-oxoclopidogrel y sus sales farmacéuticamente aceptables del mismo se describen para el tratamiento o profilaxis de enfermedades de trombo-embolismo y/o cardiovasculares.
MX2013014946A 2011-06-27 2012-01-06 Compuestos antitromboticos. MX344435B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1848MU2011 2011-06-27
PCT/IN2012/000021 WO2013001544A1 (en) 2011-06-27 2012-01-06 Anti-thrombotic compounds

Publications (2)

Publication Number Publication Date
MX2013014946A MX2013014946A (es) 2014-02-17
MX344435B true MX344435B (es) 2016-12-14

Family

ID=45495857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014946A MX344435B (es) 2011-06-27 2012-01-06 Compuestos antitromboticos.

Country Status (13)

Country Link
US (6) US20120329762A1 (es)
EP (2) EP2675813A4 (es)
JP (1) JP2014518260A (es)
KR (1) KR20140047082A (es)
CN (1) CN104245707A (es)
AU (1) AU2012277327B2 (es)
BR (1) BR112013033464A2 (es)
CA (1) CA2839608C (es)
MX (1) MX344435B (es)
RU (1) RU2604733C2 (es)
SG (1) SG195257A1 (es)
WO (1) WO2013001544A1 (es)
ZA (1) ZA201309411B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN107698620A (zh) 2015-06-23 2018-02-16 江苏天士力帝益药业有限公司 一种氘代噻吩并哌啶衍生物、制备方法及其应用
CN107304215A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
CN108685913B (zh) * 2018-07-31 2021-08-10 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及制备方法和应用
CN109912595B (zh) * 2019-03-29 2020-08-25 成都施贝康生物医药科技有限公司 一种抗炎药物及其用途
CN111943958B (zh) * 2019-05-17 2023-05-09 成都施贝康生物医药科技有限公司 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用
CN112076190B (zh) * 2019-06-14 2023-04-07 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
WO2021070200A2 (en) * 2019-10-08 2021-04-15 Ipca Laboratories Limited Stable compositions of (7as,2's)-2-oxoclopidogrel and its pharmaceutical salts
CN111249241B (zh) * 2020-01-19 2023-06-27 成都施贝康生物医药科技有限公司 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN111150731A (zh) * 2020-01-19 2020-05-15 成都施贝康生物医药科技有限公司 含氧吡格雷光学异构体或其盐的组合物及应用
CN111138450B (zh) * 2020-01-19 2024-04-19 成都施贝康生物医药科技有限公司 一种抗炎化合物及其制法和用途
CN115327004B (zh) * 2022-08-12 2024-01-26 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷粗品的检测方法
CN115327003B (zh) * 2022-08-12 2024-03-12 成都施贝康生物医药科技有限公司 一种氧化氯吡格雷有关物质的检测方法
CN115429797A (zh) * 2022-08-31 2022-12-06 成都施贝康生物医药科技有限公司 一种含氧氯吡格雷或其盐的组合物及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) * 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
JPH10310586A (ja) * 1996-06-26 1998-11-24 Sankyo Co Ltd ヒドロピリジン類の新規医薬用途
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CN101885730B (zh) * 2009-05-13 2012-07-04 连云港恒邦医药科技有限公司 抗血栓的化合物
CN102120744B (zh) * 2010-02-02 2013-01-09 江苏威凯尔医药科技有限公司 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
CN102212069A (zh) * 2010-04-06 2011-10-12 刘桂坤 环烷衍生物及其制备方法和在心脑血管病药物上的应用
RU2611662C2 (ru) * 2010-08-26 2017-02-28 Ипка Лэборэториз Лимитед Способы лечения или профилактики тромбообразования или эмболии

Also Published As

Publication number Publication date
JP2014518260A (ja) 2014-07-28
SG195257A1 (en) 2013-12-30
US20120329762A1 (en) 2012-12-27
RU2604733C2 (ru) 2016-12-10
US20140031320A1 (en) 2014-01-30
RU2014102362A (ru) 2015-08-10
CA2839608A1 (en) 2013-01-03
NZ618694A (en) 2016-03-31
US8536337B2 (en) 2013-09-17
CN104245707A (zh) 2014-12-24
EP2675813A4 (en) 2014-04-30
US20140038924A1 (en) 2014-02-06
US10105353B2 (en) 2018-10-23
CA2839608C (en) 2020-07-14
BR112013033464A2 (pt) 2017-01-24
WO2013001544A1 (en) 2013-01-03
KR20140047082A (ko) 2014-04-21
ZA201309411B (en) 2014-08-27
US20130316987A1 (en) 2013-11-28
EP2540729A1 (en) 2013-01-02
US20120329763A1 (en) 2012-12-27
AU2012277327A1 (en) 2014-01-09
AU2012277327B2 (en) 2017-04-27
US20130316986A1 (en) 2013-11-28
MX2013014946A (es) 2014-02-17
EP2675813A1 (en) 2013-12-25
WO2013001544A9 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
SG195257A1 (en) Anti-thrombotic compounds
PH12016501750A1 (en) Human plasma kallikrein inhibitors
IN2015DN01156A (es)
MX2023001876A (es) Derivados de rapamicina.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
MY162936A (en) Macrocycles as factor xia inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
NZ703064A (en) Inhibitors of hepatitis c virus
MX361759B (es) Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico.
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
PH12015500376A1 (en) Novel bicyclic pyridinones
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
IN2014DN09347A (es)

Legal Events

Date Code Title Description
FG Grant or registration